The landmark PANTHEON trial, a 1-year multicenter RCT in 1,006 Chinese COPD patients, found that high-dose NAC (600 mg twice daily) reduced the rate of acute exacerbations by 22% compared to placebo (1.16 vs 1.49 exacerbations per year, p=0.0011) (Zheng et al., Lancet Respir Med, 2014) [44]
Key findings highlight PPRs bioavailability-enhancing and neuroprotective properties, yet its inhibition of CYP3A4/P-gp elevates toxicity risks for carbamazepine (68.7% plasma concentration) and warfarin
Long term Ipamorelin research has not shown any major safety concerns but researchers emphasize proper dosing and administration protocols
Mind your timing Separate antifungals and probiotics by ~1 hour (see our guide to timing them)
Future perspective Future developments in nano-lipid carrier composition will maximize drug encapsulation, stability, and shelf life
When acclimating to increased levels of oxidative stress, SOD concentrations typically increase with the degree of stress conditions